TB DRUG SCREENING:TB ANTIMICROBIAL ACQ & COORD. FACILITY

这项合同提供了与学术机构和私营部门的接口，以评估新类别的化合物对抗结核活性的作用。这一收购部分积极争取药物化学家，并寻求学术文献和通过制药公司储存库确定的化合物中描述的化学品和天然产品。合同充当测试前代理的中央存储库。所有化合物都根据保密协议进行测试，新化合物将在现有的化学结构数据库中登记，以避免重复测试。目前合同中的探索重点将是化合物，以杀死潜伏在疾病潜伏期的静止或休眠的结核杆菌。承包商负责向供应商提供生物数据，并作为进一步药物开发互动的中心联系人。

This contract provides the interface with academic establishments and the private sector for evaluation of new classes of compounds for activity against M. tuberculosis. This acquisition component actively canvases medicinal chemists and pursues chemicals and natural products described in the academic literature and in compounds identified via pharmaceutical company repositories. The contract serves as the central storage repository of agents prior to testing. All compounds are tested under a confidentiality agreement and new compounds will be registered with the existing chemical structure database to avoid duplicative testing. The emphasis for exploration in the current contract will be for compounds to kill quiescent or dormant tubercle bacilli present in the latent phase of disease. The contractor is responsible for supplying biological data to the suppliers and for serving as a central contact for further drug development interactions.